Acute Pain News and Research RSS Feed - Acute Pain News and Research

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

AcelRx Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency, has adopted a positive opinion for Zalviso (sufentanil sublingual tablets). [More]
Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. [More]
Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology. [More]
ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). [More]

New evidence-based protocol to treat severe pain in emergency department patients

Simply asking the question, "Do you want more pain medication?" resulted in satisfactory pain control in 99 percent of emergency department patients participating in a study. [More]
US patients undergoing orthopaedic surgery receive more treatments for pain

US patients undergoing orthopaedic surgery receive more treatments for pain

New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. [More]
Canadian researchers shed light on molecular dynamics of chronic pain

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain. [More]
Specific brain chemical may play role in promoting chronic pain

Specific brain chemical may play role in promoting chronic pain

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas. [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
Markovian models show promise for describing postoperative pain trajectories

Markovian models show promise for describing postoperative pain trajectories

Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found. [More]

AAPM announces 2015 Presidential Commendations for exceptional service in Pain Medicine

The American Academy of Pain Medicine is pleased to announce its 2015 Presidential Commendations for exceptional service to the Academy and/or the field of Pain Medicine. [More]
AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain. [More]
Study investigates effects of antidepressant treatment in pain catastrophizing patients

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain. [More]
AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. [More]
New poll finds pain as key correlates of shorter sleep durations, worse sleep quality

New poll finds pain as key correlates of shorter sleep durations, worse sleep quality

A new poll by the National Sleep Foundation finds that pain is a key factor in the gap between the amount of sleep Americans say they need and the amount they're getting - an average 42 minute sleep debt for those with chronic pain and 14 minutes for those who've suffered from acute pain in the past week. [More]
ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals, Inc. today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. [More]
National Spine & Pain Centers opens new pain management center in Cumberland, Maryland

National Spine & Pain Centers opens new pain management center in Cumberland, Maryland

Over 100 million adults suffer from chronic pain and about half of those suffer from this pain daily. Chronic and acute pain dramatically impacts quality of life. The specialty of pain management is born to fulfill the need for non-surgical, interventional solutions and medication management to treat all types of pain. [More]
Alliance for Balanced Pain Management established to support appropriate access to pain management

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. [More]
Advertisement